Pfizer Inc. Stock
€23.70
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 1.350% | -3.627% | 0.343% | 12.753% | 9.892% | -38.541% | -22.694% |
| BioMarin Pharmaceutical Inc. | 0.540% | 1.443% | -7.900% | -10.550% | -4.715% | -46.832% | -26.292% |
| Johnson & Johnson | 0.360% | -2.766% | -0.724% | 49.130% | 16.357% | 36.012% | 49.238% |
| Biogen Inc. | 1.240% | -4.515% | -4.904% | 38.745% | 1.061% | -42.331% | -32.961% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Why Pfizer Stock Tumbled on Tuesday
On the second trading day of the week, Pfizer (NYSE: PFE) was a laggard on the stock exchange. An analyst reiterated his bearish view of the stock, and more than a few investors were obviously
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today
One of the most puzzling stocks these days is Pfizer (NYSE: PFE). Although it's not generating tons of money from its COVID vaccine and pill anymore, the business is still doing well. There are
Prediction: Buying Pfizer Stock Today Could Set You Up for Life
Pfizer (NYSE: PFE) investors got some very bad news when the company was forced to abandon its internally developed GLP-1 weight loss drug in April, 2025. With patent expirations on the horizon